Medical Cannabis and biotech breakthroughs are reshaping medicine.

Biotech advances, shifting policy, and growing clinical evidence have brought medical cannabis into broader biomedical research, with developments such as lab-made cannabinoids, targeted therapies, AI-driven discovery, and current use in pain management and epilepsy.

Medical cannabis has shifted from the margins into mainstream biomedical research. A combination of biotechnology, clinical study, and policy changes has driven renewed attention. Researchers now focus on the endocannabinoid system and how cannabinoids interact with it. Companies and clinicians are exploring standardized, targeted treatments that use specific cannabinoids and engineered compounds. Key developments: - The endocannabinoid system (CB1 and CB2) is central to current research and is reported to regulate pain, inflammation, mood, sleep, immune function, appetite, and neuroprotection. - Pharmaceutical-grade cannabinoids are being produced synthetically or by biosynthesis to enable precise dosing, more consistent manufacturing, and use in clinical trials. - Targeted cannabinoid therapies are being developed, including CBD-heavy formulations, THC–CBD blends, CBG-focused approaches, and THCV research aimed at specific conditions. - AI is being used to predict effective cannabinoid combinations and to accelerate discovery of novel compounds. - Medical and real-world use reported in the article includes chronic pain management, treatment-resistant epilepsy (with CBD use noted in severe childhood syndromes), mental health support, inflammatory and autoimmune conditions, cancer symptom management, and early research into neurodegenerative diseases. Summary: Biotechnology and expanding clinical evidence have turned cannabis into a platform for precision drug development and wider clinical study. Undetermined at this time.